Portable MRI enhanced by AI cleared for prostate imaging

A manufacturer of compact MRI machines that leverage AI to upgrade image quality has received FDA’s blessing to market its technology in the U.S.

Oakland, California-based Promaxo announced the development March 8, saying the agency had granted 510(k) clearance for its product to be used in image-guided prostate procedures such as biopsies.

The company says the system is small enough for installation in urologists’ offices and outpatient surgery suites, no shielding or facility upgrades needed.

The product “incorporates patented technologies to capture, reconstruct and display magnetic resonance images of prostate and surrounding tissues,” Promaxo says. “The proprietary device leverages pre-programmed sequences and artificial intelligence to enhance image quality.”

Announcement here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

Suman Tandon, MD, an American Society of Nuclear Cardiology board member, explains the group's call on Congress to update a number of healthcare policies. 

The 2026 MPFS proposed rule includes higher conversion factors across the board. However, some cardiology groups remain concerned about a series of reimbursement reductions for high-value cardiology services.